The company's product portfolio includes EVO756 for treating chronic spontaneous urticaria and atopic dermatitis, and EVO301 for treating atopic dermatitis and ulcerative colitis. Evommune completed its IPO on the NYSE in November 2025 via a $150 million offering to fund clinical-stage candidates.
Cyborg Score Rationale
Early-stage biotech with recently completed IPO showing strong investor confidence ($150M raised). Two late-stage clinical programs in high-need inflammatory disease indications with significant market opportunity. However, clinical-stage status carries significant execution risk with no approved products or revenue.
Top Insights
Completed successful IPO in November 2025 at $16/share, raising $150M for pipeline advancement
Focused two-asset strategy (EVO756 and EVO301) targeting high-prevalence inflammatory diseases with limited treatment options
Clinical-stage company with no current revenue; unprofitable with success dependent on trial outcomes
Market cap approximately $878M as of March 2026, with analyst price targets suggesting 50% upside potential
Named Competitors
Inflammatory disease programs — Clinical-stage biotech with $250M Nasdaq IPO; develops therapies for inflammatory conditions
Dermatology/immunology programs — Focused on dermatology and immunology therapeutic solutions
Recent Developments
(November 2025) IPO completion on NYSE at $16/share for $150 million gross proceeds
(February 2026) Stock surged 64-70% on positive clinical trial announcements
(March 2026) Analyst upgrades with Evercore ISI raising price target to $55 from $40
Open the full interactive Evommune, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.